Novo Nordisk sued over weight-loss drug spin. Now it’s doing the exact same thing
Top Story
Archived
•
September 22, 2026
•
Novo Nordisk and Eli Lilly are battling for dominance in one of medicine’s largest and fastest-growing markets: drugs for obesity and weight loss. On Monday, Novo announced encouraging results for its experimental drug CagriSema. In a Phase 3 study of patients with type 2 diabetes, CagriSema produced 12.4% average weight loss after 60 weeks, compared […]
Source: Washington Examiner | https://www.washingtonexaminer.com/feed - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



